- Letter to the Editor
- Open access
- Published:
Good practices for Ga-68 radiopharmaceutical production: an important correction
EJNMMI Radiopharmacy and Chemistry volume 8, Article number: 1 (2023)
To the editor
The review titled “Good practices for 68Ga radiopharmaceutical production” by Nelson et al. (2022) and published in the latest issue of your journal contains important information about 68Ga radiopharmaceuticals. However, sentence of the “These 68Ga radiopharmaceuticals include agents such as [68Ga]Ga-macroaggregated albumin for myocardial perfusion evaluation…” contradicts basic nuclear medicine knowledges.
68Ga-macroaggregated albumin is stated to be a potential radiopharmaceutical in lung perfusion studies in preclinical and clinical studies (Gültekin et al. 2020; Ament et al. 2013). 68Ga-macroaggregated albumin is not used in myocardial perfusion studies. I think that this error maybe caused by inattention of the author and in the review processes, and I would like to point out that it would be useful to correct it.
Availability of data and materials
Not applicable.
References
Ament SJ, Maus S, Reber H, Buchholz HG, Bausbacher N, Brochhausen C, Graf F, Miederer M, Schreckenberger M. PET lung ventilation/perfusion imaging using (68)Ga aerosol (Galligas) and (68)Ga-labeled macroaggregated albumin. Recent Results Cancer Res. 2013;194:395–423. https://doi.org/10.1007/978-3-642-27994-2_22.
Gültekin A, Çayır M, Uğur A, Bir F, Yüksel D. Detection of pulmonary embolism with Gallium-68 Macroaggregated Albumin Perfusion PET/CT: an experimental study in rabbits. Contrast Media Mol Imaging. 2020;2020:5607951. https://doi.org/10.1155/2020/5607951.
Nelson BJB, Andersson JD, Wuest F, Spreckelmeyer S. Good practices for 68Ga radiopharmaceutical production. EJNMMI Radiopharm Chem. 2022;7(1):27. https://doi.org/10.1186/s41181-022-00180-1.
Acknowledgements
Not applicable.
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
AG was responsible for writing and editing the manuscript. The author read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethical approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The author declares that they have no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gültekin, A. Good practices for Ga-68 radiopharmaceutical production: an important correction. EJNMMI radiopharm. chem. 8, 1 (2023). https://doi.org/10.1186/s41181-022-00184-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s41181-022-00184-x